Milestone Pharmaceuticals (MIST) Competitors

Voyager Therapeutics (NASDAQ:VYGR) and Milestone Pharmaceuticals (NASDAQ:MIST) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their dividends, earnings, valuation, risk, profitability, community ranking, institutional ownership, analyst recommendations and media sentiment.

Does the media favor VYGR or MIST?

In the previous week, Voyager Therapeutics had 6 more articles in the media than Milestone Pharmaceuticals. MarketBeat recorded 7 mentions for Voyager Therapeutics and 1 mentions for Milestone Pharmaceuticals. Milestone Pharmaceuticals' average media sentiment score of 1.89 beat Voyager Therapeutics' score of 0.51 indicating that Milestone Pharmaceuticals is being referred to more favorably in the news media.

Company	Overall Sentiment
Voyager Therapeutics	Positive
Milestone Pharmaceuticals	Very Positive

Does the MarketBeat Community prefer VYGR or MIST?

Voyager Therapeutics received 316 more outperform votes than Milestone Pharmaceuticals when rated by MarketBeat users. However, 68.55% of users gave Milestone Pharmaceuticals an outperform vote while only 67.97% of users gave Voyager Therapeutics an outperform vote.

Company	Underperform	Outperform
Voyager Therapeutics	Outperform Votes 401 67.97%	Underperform Votes 189 32.03%
Milestone Pharmaceuticals	Outperform Votes 85 68.55%	Underperform Votes 39 31.45%

Do institutionals and insiders believe in VYGR or MIST?

48.0% of Voyager Therapeutics shares are owned by institutional investors. Comparatively, 86.2% of Milestone Pharmaceuticals shares are owned by institutional investors. 4.5% of Voyager Therapeutics shares are owned by company insiders. Comparatively, 9.9% of Milestone Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Is VYGR or MIST more profitable?

Voyager Therapeutics has a net margin of 15.80% compared to Milestone Pharmaceuticals' net margin of 0.00%. Voyager Therapeutics' return on equity of 8.33% beat Milestone Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Voyager Therapeutics	15.80%	8.33%	6.15%
Milestone Pharmaceuticals	N/A	-151.82%	-49.85%

Do analysts rate VYGR or MIST?

Voyager Therapeutics presently has a consensus target price of $13.97, suggesting a potential upside of 302.49%. Milestone Pharmaceuticals has a consensus target price of $17.00, suggesting a potential upside of 1,228.13%. Given Milestone Pharmaceuticals' higher possible upside, analysts clearly believe Milestone Pharmaceuticals is more favorable than Voyager Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Voyager Therapeutics	0 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	3.11
Milestone Pharmaceuticals	0 Sell rating(s)	3 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.40

Which has preferable earnings & valuation, VYGR or MIST?

Voyager Therapeutics has higher revenue and earnings than Milestone Pharmaceuticals. Voyager Therapeutics is trading at a lower price-to-earnings ratio than Milestone Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Voyager Therapeutics	$80.00M	2.39	$132.33M	-$1.13	-3.07
Milestone Pharmaceuticals	$1M	68.29	-$59.69M	-$0.68	-1.88

Which has more risk and volatility, VYGR or MIST?

Voyager Therapeutics has a beta of 1.02, indicating that its share price is 2% more volatile than the S&P 500. Comparatively, Milestone Pharmaceuticals has a beta of 1.38, indicating that its share price is 38% more volatile than the S&P 500.

Summary

Voyager Therapeutics beats Milestone Pharmaceuticals on 11 of the 19 factors compared between the two stocks.